Stellar Pharmaceuticals
English        Pour nous joindre     1-800-639-0643          

Navigation

Pour nous joindre

Stellar Pharmaceuticals Inc.
54, rue Egerton
London (Ontario) N5W 3Z8
Tél. : 1-800-639-0643
Fax : 519-434-4382

Communiqués de presse

 1    
Date de sortie Titre (cliquer pour lire)
01/02/2013 Stellar Pharmaceuticals Announces Name & Ticker Change to Tribute Pharmaceuticals Canada Inc. and 'TBUFF'; Issues Letter to Shareholders
11/28/2012 Stellar Pharmaceuticals Appoints Chief Scientific Officer to Support Growing Product Portfolio
11/13/2012 Stellar Pharmaceuticals Shows Strong Third Quarter Revenue Growth to $3.2 Million
11/13/2012 Stellar Pharmaceuticals Shows Strong Third Quarter Revenue Growth to $3.2 Million
10/04/2012 Stellar Pharmaceuticals Launches New Migraine Treatment, CAMBIA(R), in $150 Million Canadian Prescription Migraine Market
08/23/2012 Stellar Pharmaceuticals Enters Into a Partnership With Pfizer Canada Inc. to Promote Gelfoam(R) in Canada
08/14/2012 Stellar Pharmaceuticals Reports Second Quarter and First Half 2012 Financial Results
06/20/2012 Stellar Pharmaceuticals Acquires the Exclusive Rights to Collatamp G(R) in Canada
06/11/2012 Stellar Pharmaceuticals to Present at the Bloom Burton Investor Conference June 21
05/15/2012 Stellar Pharmaceuticals Reports First Quarter 2012 Financial Results
05/14/2012 Stellar Pharmaceuticals Inc. Secures US$6.0 Million Term Loan to Support Market Growth
04/02/2012 Stellar Pharmaceuticals Strong Product Sales in 2011; Builds for the Future
03/29/2012 Stellar Pharmaceuticals Inc.: Shareholder Early Warning News Release
03/21/2012 Stellar Pharmaceuticals Inc. Announces Correction to Conference Call Access Number Dated March 19, 2012
03/19/2012 Stellar to Hold Conference Call re Health Canada Approval of CAMBIA(R) for the Treatment of Acute Migraines
03/16/2012 Health Canada Approves CAMBIA(R) for the Treatment of Acute Migraine
01/26/2012 Stellar Pharmaceuticals Receives 2nd Uracyst(R) Patent in United States of America
01/03/2012 Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa(TM) for Onychomycosis
01/03/2012 Stellar Pharmaceuticals Inc.: Conference Call
01/03/2012 Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa(TM) for Onychomycosis
 1    
© 2024 Stellar Pharmaceuticals Inc. Tous droits réservés.